Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status
Lucía Carril-Ajuria, Émeline Colomba, Carmen Romero, Luigi Cerbone, Raffaele Ratta, Philippe Barthélémy, Clarisse Vindry, Aude Fléchon, François Cherifi, Elouen Boughalem, Claude Linassier, Giuseppe Fornarini, Sara Elena Rebuzzi, Marine Gross‐Goupil, Carolina Saldana, Maricruz Martín-Soberón, Guillermo de Velasco, Ray Manneh Kopp, Cristina Pernaut, Ana Sanchez de Torre, Ronan Flippot, Bernard Escudier, Laurence Albigès
Topics & Concepts
MedicineNivolumabRenal cell carcinomaIpilimumabPembrolizumabInternal medicineAxitinibOncologyPerformance statusAdverse effectCombination therapyResponse Evaluation Criteria in Solid TumorsNephrectomyCancerProgressive diseaseImmunotherapyChemotherapySunitinibKidneyRenal cell carcinoma treatmentCancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments